title: H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage.
abstract: Liver disease alters the pharmacokinetic and pharmacodynamic properties of hepatically eliminated drugs. The main factors influenced are plasma albumin levels, enzyme balance (induction & inhibition) and drug binding to tissue proteins. The influence of lidocaine on serum, heart and liver propranolol levels in Wistar rats after liver injury induced by carbon tetrachloride CCl4 0.4 ml/kg x 2/wkl, was investigated. 40 male Wistar rats were divided into four groups (I, II, III, IV; n=10), Group I animals received only propranolol (labelled + cold substance) 40 mg/kg/12 h p.o., group II propranolol plus lidocaine in a single dose of 4mg/kg s.c., group III was treated with CCl4 for 6 weeks and received propranolol x2 at the same dosage as group I, while group VI was treated with CCl4 and the same drug dosage as group II. The simultaneous administration of H3-propranolol and lidocaine increased propranolol levels in the serum and tissues. The liver in damaged animals showed an increase of propranolol level under lidocaine co-administration, probably due to CCl4 induced liver enzyme activity, resulting in a rapid propranolol metabolism or to competition between both drug protein binding sites. The increased propranolol levels in the heart after lidocaine administration were probably due to attributed to its high affinity for heart tissue. Consequently, as regards the therapeutic approach for patients with liver disease receiving propranolol their propranolol dosage should be reduced when lidocaine is co-administered.
authors.affiliation: Department of Pharmacology, Medical School, University of Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Kotsiou
authors.forename: M
authors.initials: M
authors.lastname: Tsamouri
authors.forename: S
authors.initials: S
authors.lastname: Anagnostopoulou
authors.forename: M
authors.initials: M
authors.lastname: Tzivras
authors.forename: E
authors.initials: E
authors.lastname: Vairactaris
authors.forename: C
authors.initials: C
authors.lastname: Tesseromatis
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000097:blood* / Q000378:metabolism; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D002251:Carbon Tetrachloride; D004347:Drug Interactions; D008012:Lidocaine / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009206:Myocardium / Q000378:metabolism; D011433:Propranolol / Q000097:blood* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014316:Tritium
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D014316:Tritium; D008012:Lidocaine; D011433:Propranolol; D002251:Carbon Tetrachloride